Good morning everyone. I am Marcelo, CFO of Ourofino Saúde Animal.

It's a great pleasure to have you all here, all of our stockhold investors, and we have the result of quarter 4 2025. We have starting with us the CEO, and we are going to talk a little about our goals, and I'll come back later talking about our financial closing.

Now we call Kleber. Hello.

Good morning Marcelo, good morning everyone. It's a pleasure to be here.

It's a pleasure to be here to present you the results of the quarter 4 of 2025. We are very proud of what we have delivered so far.

It's a journey that it comes from different decisions we have made, and we have managed the company for the different angles, and we are doing this to have the sales much more faster, and our closing the 2025 with positive results.

We are growing very fast and strong. It's very above the the market, totally different than we have seen.

This the fourth quarter very consolidated. We grow around 20% of year.

All the areas are growing in quality. We have here the the income growth, net income growth, which is more than revenue, and also we had also an adjusted growth which which brought a tribute of values, but we have a very elevated value.

We had growth around 30%. This is important because we had a positive result which which we had enhanced it all the recipes, and also the the revenues.

We have seen we had a very long chain, but now we're going to present some results of five, four years ago. We have been showing the good results in 2024, but of course 2025 we had a very good net revenue because we had very good products.

We still having and enjoying the good results we had. I'm sure we have the products which still bring good results.

Of course, we have a few make, but this is a very important because it shows how good we are and how good we have been bringing. Of course, this is we have to remind that we just got this growth because we have a very good union of the the team, because we have a very passionate group and they have been and we are living the brand of Ourofino every day.

We are very happy with the results. I'm going to highlight some launching.

Some things happened in the third quarter, but the others in the fourth one. We have some rupture, important information and and revenue.

Also, we had having a very strategic with the Korean company. We have also a post-patent closing, which is the NexGard, which is for cows, which is a very complex treatment, which is very important for tropical agriculture and also when we talk about cattle, the European cattle which suffers a lot with tick.

Also we have WellPet, which is for companion pets. Also some other products which are developed, which are very differentiated from the other products in the market.

We have here the WellPet, which is a pill which is palatable and it has a protection period better than the the other ones in the market. It's bringing with it very easy access, which can grow the which can bring the on the access to the ones who doesn't do this kind of protection because it brings a very good product.

We have a very differentiated product. We have another which is Sincrogest, which is a supplement, which bring which enhance the fertility in the cattle, which is one of the leaders of the market, and it comes here with very good importance in the market.

We have also the vaccines. We had one which was launched this year, which is the second in the world.

We have the biggest market of this, which is the Brazilian, and we have a very good market share, which is our vaccine to cattle. We are also consolidating our strategies.

When we go back analyzing the our strategies in the market, you're going to understand and you're going to remind that in the 2025 we had highlighted the the cattle, and poultries. We have launched other products to this area, and we are growing to and also we grow more than 40%, and now we had growth 30%.

The focus we have been doing, it's it has been very important. As just summary of the year, it's it was a year that we closed almost every indicators of the company.

We're going to discuss this later on. Of course, it was a very good governance work, which has been very important.

We have been we're doing it ongoing. We also closed a very business cycle.

Now we have a 20 30 it's We are accelerating the path to the partnerships, international partnerships, this is very important. We have been working this strategies.

Also, we have a very good work being doing the product governance. Seeing that we're in a very good path, we're have been working very close, and the team has been doing a very good work, a very good base to show that for the future years we have been we are going to succeed as we have been fighting for.

After later on I'll be back in the Q&A. Now I'm going to pass to give this stage to Marcelo.

Marcelo, it's with you now.

We have been seeing figures very well consolidated. We can see here in the the fourth quarter 2024 and 2025 we have been growing.

We had from in the accumulated 19.5. Something very important to understand it's that the second year in a row that we have been closing all of our gross revenue, which we had in 20 25 27.7, but in comparison to the previous year we had a growth.

Also we had a very important net income, which was 17.2, but we got 14.1%, and this reflects, which was in a year much more favorable year, and we had many products which were which are now in the first or in the second market position in market. Then we have been seeing this.

Also, we we have seen the company going down the expenses, and this is important too. Also we had the EBITDA, which had 24.7.1, but in the the year was 27.7%.

This reflects the reduced expenses of the company, but also preserving the core and the search and development of the company. Also we have net income, which grow 17.2, but in the accumulated we have 14.1, which was in collection of capital, which is reflecting our profile of investment.

We had the net income more than the company, also we had the growth of the EBITDA, and also the income net growth more than EBITDA as well. Now we have a very detailed information here: the consolidated results.

We had in the quarter a growth of 23.2, and accumulated as 19.5. We have here a consolidated that was 46.

40.6%, which is higher than the other years. It's although it was the best net income in the animal segments, always reminding the capacity of the company to generate value to the whole the whole market.

We have here the companion animals results. We have been following that in 2025 it was a little less warmed, but we still have a very improved growth, which was 10.4%, and we had a growth in the quarter in 20 4% that Kleber has mentioned previously.

We had also a growth in gross profit 71.3. Also reminding that the company has a very good ability and is bringing to grow this, and also we had the net revenue that was that it grows to 10.4%, which reflects the investments of the company to grow in the whole market of companion animals.

Other things we have to mention is the international operations. We have here the net revenue at 8.4%, which is higher in Brazil's.

Of course we have a very strategic market, but also we have the fluctuation and also other financially important issues. This also reflects our right of operations, because it brings the imported products.

Also we have a very good impor- a very important results in the international operation. Of course, we have very good work in the the branches in Mexico and other countries.

It was a very important growth because it reflects the the commitment of the company to the international operations agenda. We had an adjustment to the expenses.

We had a going down which reflects the the commitment of the company which brings the 27.5 dilution of these expenses, which brings the the margin higher than the growing. It's very important.

Also we have the R&D investments we brought here, which 6.4 because we have we had lots of good projects. In this year we had lots of releases, and and then we had the costs of the R&D in 2024, but this percentile is like 6.4%, which round.

It's important to understand this investment is compared to the big companies' and data's, to look it's closer to. We have this in a continuous opportunities and strategies of course.

As we have here a figures of the the company, which was 27.4, but I want to highlight not only the growth of the sell sales, but also the revenue the cash availability. We had 100 millions, which is higher than the cash availability in 2024.

The company has kept this cycle of growing of the net of the cash availability, what has been representing that a good management of this cash, and which makes us much more comfortable to to work in this growth, but also not only in the sales, but also in the cash availability. Also in a year we delivered penniers values at 20 200.8 million, and this and which represents a very healthy money cash availability.

Also we have here this structure capital structure because it triggers a very good growth, which is 0. 85, which is accelerated, which is less in the market, which is less than EBITDA, considering that the expenses is is related to our investment profile, which is concentrated in the credit, which is allowed to development, which brings the rate of 50% max.

Also we have an expenses which brings the cost of capital, which is direct to our investment profile, which is very long in our cycle. We had a very below expenses that like 4 39.4% in more than 5 years, and we have seen how this is committed to the interest payments, and it's a very comfortable moment of the company because it shows that our investment agenda is very committed to the market, mainly to the releases new to release new products.

We have finished, we have closed the financial information. Now we have we are opening the Q&A to Kleber.

Just

taking a look at the chat, but we have no questions so far. Just a minute.

We have one. One?

I wasn't able to read the questions. There's a question to explore a little bit more our strategic plan.

Regarding our strategic plan, we are following the same path, as we can say that way. We have the plan to intensify our growing in the Latin American.

We have been working with Mexico, also we have a very respected image, and we can see that this is a very important investment. Also, we have been investing in biologics.

We also have some plans because we have some global products, but we also need to prepare the company. We have efficiency agenda, which is very important, especially to collect new market opportunities, which represents an enhancement of marketing, sales, and we have been working in a very important agenda to develop this groups.

Of course, we still have a lot. Of course, we have a products agenda, which has been collecting the products with has the best opportunities in the market.

Of course, we still have an organic agenda, but it's related to the partners I had mentioned so far. Of course, our commitment is to bring the company as the most admirable company in the world.

Also, there's another question regarding a plan of extraordinary distribution of expenses. We don't have it, but we have an agenda for the next assemblies.

Of course, we're going to have this above the minimum. Of course, we have the cash to have this money.

Of course, we must have the agreement of the authorization board. Of course, we have in the future as a purpose in a project of distribution of expenses.

There's another question, what is the level of growth of 2026? We can't say for sure.

We have a guidance to follow, but we want to grow more than the previous year. We had, as I mentioned before, we had some products which was released at the end of the year, we still have a lot to consolidate of revenue that it's important to guarantee the goals we still have.

We need to follow the guidance, and then in the future on, we are going to have more information. That were the questions.

There were no other ones. We want to thank for our stockholds, mainly ones Mitsui, which is in Ourofino board, which are always working to bring the best results.

Also, our business partners, our clients, which has been working with or financing. We have to remind that without this structure, we wouldn't be able to do anything.

It's important to understand that, and we hope you all have a very good 2026, and this is what we committed here. Now I give this stage to Marcelo.

Thank you, Kleber. I will also thank you all, everyone that supports our work here.

The RI team is always ready to answer any doubts you have, and we hope that 2026 is very prosperous to everyone.